Fortvita Biologics Receives Positive EMA CHMP Opinion for Zybrivo in First-Line Lung Cancer Treatment

17 November 2026 | Tuesday | News

The European Medicines Agency's CHMP has recommended approval of Zybrivo (sintilimab) in combination with chemotherapy for eligible adults with advanced non-squamous non-small cell lung cancer. The recommendation follows Phase 3 ORIENT-11 results showing a 52% reduction in the hazard of disease progression or death and a 35% reduction in the hazard of death compared with chemotherapy alone. A final European Commission decision is expected in the coming months
Image Source: Public Domain

Image Source: Public Domain

Fortvita Biologics (Fortvita), a member of the Innovent Group (Innovent Biologics, Inc., HKEX Stock Code: 01801), announced that it has received its first positive opinion from the CHMP of the European Medicines Agency (EMA). The CHMP recommends marketing authorization of Zybrivo® (sintilimab) in combination with chemotherapy for the first-line treatment of eligible adults with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo would provide eligible patients across Europe with access to another first-line treatment option. The positive opinion is supported by results from the Phase 3 ORIENT-11 study (NCT03607539).

"This positive CHMP opinion marks a significant milestone in Fortvita's globalization journey and reinforces our commitment to bringing innovative therapies to patients worldwide," said Jamie Freedman, MD, PhD, Chief Medical Officer of Fortvita. "Europe is a key pillar of Fortvita's globalization strategy to bring innovative medicines to patients beyond China. As we await the European Commission's decision, we are strengthening our capabilities to support patient access across key European markets. If approved, Zybrivo would be our first medicine to advance this strategy, offering an additional treatment option for eligible patients with advanced non-squamous non-small cell lung cancer and paving the way for future therapies from our growing pipeline."

Following the CHMP's positive opinion, the European Commission is expected to issue a final decision on marketing authorization in the coming months. If approved, the authorization will be valid across all 27 European Union (EU) member states, as well as Iceland, Norway, and Liechtenstein.

Sintilimab is an immunotherapy consisting of a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).

The CHMP recommendation is based on results of ORIENT-11, a randomized, multicenter, double-blind, placebo-controlled Phase 3 study that enrolled 397 adult patients with locally advanced, metastatic or recurrent non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations, regardless of programmed death-ligand 1 (PD-L1) expression. Patients were randomized 2:1 to receive sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), assessed by a blinded independent radiological review committee.

In ORIENT-11, sintilimab plus chemotherapy demonstrated a 52% reduction in the hazard of disease progression or death (median PFS: 8.9 vs. 5.0 months) and a 35% reduction in the hazard of death (median overall survival (OS): 24.2 vs. 16.8 months), compared with placebo plus chemotherapy.

These results demonstrate the clinical benefit of sintilimab in combination with chemotherapy and its potential to offer an additional first-line treatment option for eligible patients with advanced non-squamous NSCLC in Europe.

The safety profile of sintilimab in combination with chemotherapy was consistent with the known safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals identified. Additional details may be found at clinicaltrials.gov, using identifier NCT03607539.

Zybrivo in combination with pemetrexed and platinum-based chemotherapy is indicated for the first line treatment of adult non-squamous non-small cell lung cancer (NSCLC) patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, and who have:
     •  locally advanced NSCLC and are not candidates for curative intent surgical resection or chemoradiation, or
     • metastatic NSCLC.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close